Literature DB >> 24845066

Prevalence of potentially inappropriate medications and risk of adverse clinical outcome in a cohort of hospitalized elderly patients: results from the REPOSI Study.

L Pasina1, C D Djade, M Tettamanti, C Franchi, F Salerno, S Corrao, A Marengoni, M Marcucci, P M Mannucci, A Nobili.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: Inappropriate prescribing is highly prevalent for older people and has become a global healthcare concern because of its association with negative health outcomes including ADEs, hospitalization and resource utilization. Beers' criteria are widely utilized for evaluating the appropriateness of medications, and an up-to-date version has recently been published. To assess the prevalence of patients exposed to PIMs at hospital discharge according to the 2003 and 2012 versions of Beers' criteria and to evaluate the risk of adverse clinical events, re-hospitalization and all-cause mortality at 3-month follow-up.
METHODS: This cross-sectional study was held in 66 Italian internal medicine and geriatric wards. The sample included 1380 inpatients aged 65 years or older. Prescriptions of PIM were analysed at hospital discharge. We considered all patients with complete 3-month follow-up. RESULTS AND DISCUSSION: The prevalence of patients receiving at least one PIM was 20·1% and 23·5% according to the 2003 and 2012 versions of the Beers' criteria, respectively. The 2012 Beers' criteria identified more patients with at least one PIM than the 2003 version, although a high percentage of those patients (72·2%) were also identified by the criteria updated in 2003. The main difference in the prevalence of patients receiving a PIM according to the two versions of Beers' criteria involved prescriptions of benzodiazepines for insomnia or agitation, chronic use of non-benzodiazepine hypnotics, prescription of antipsychotics in people with dementia and oral iron at dosage higher than 325 mg/day. Prescription of PIMs was not associated with a higher risk of adverse clinical events, re-hospitalization and all-cause mortality at 3-month follow-up in both univariate and multivariate analysis, after adjusting for age, sex and CIRS comorbidity index. WHAT IS NEW AND
CONCLUSIONS: This study found no significant effect of inappropriate drug use according to Beers' criteria on health outcomes among older adults 3 month after discharge. Even though these criteria have been suggested as helpful in promoting appropriate prescribing, reducing drug-related adverse events and associated healthcare costs, to date there is no clear evidence that their application can achieve objective and quantifiable improvements in clinical outcomes. A possible explanation is that both versions of the Beers' criteria have several recognized limitations, one of the main ones being the restricted availability of some drugs in Europe or their limited prescription in everyday clinical practice.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  Beers' criteria; elderly; pharmacoepidemiology

Mesh:

Year:  2014        PMID: 24845066     DOI: 10.1111/jcpt.12178

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  19 in total

1.  Hospitalization rates during potentially inappropriate medication use in a large population-based cohort of older adults.

Authors:  Stefan Varga; Matthew Alcusky; Scott W Keith; Sarah E Hegarty; Stefano Del Canale; Marco Lombardi; Vittorio Maio
Journal:  Br J Clin Pharmacol       Date:  2017-08-04       Impact factor: 4.335

2.  Is polypharmacy an independent risk factor for adverse outcomes after an emergency department visit?

Authors:  Fabio Salvi; Lorena Rossi; Fabrizia Lattanzio; Antonio Cherubini
Journal:  Intern Emerg Med       Date:  2016-04-13       Impact factor: 3.397

3.  E-learning in order to improve drug prescription for hospitalized older patients: a cluster-randomized controlled study.

Authors:  Carlotta Franchi; Mauro Tettamanti; Codjo Dgnefa Djade; Luca Pasina; Pier Mannuccio Mannucci; Graziano Onder; Gualberto Gussoni; Dario Manfellotto; Stefano Bonassi; Francesco Salerno; Alessandro Nobili
Journal:  Br J Clin Pharmacol       Date:  2016-04-05       Impact factor: 4.335

Review 4.  Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register.

Authors:  Pier Mannuccio Mannucci; Alessandro Nobili; Luca Pasina
Journal:  Intern Emerg Med       Date:  2018-08-31       Impact factor: 3.397

Review 5.  Tools for Assessment of the Appropriateness of Prescribing and Association with Patient-Related Outcomes: A Systematic Review.

Authors:  Nashwa Masnoon; Sepehr Shakib; Lisa Kalisch-Ellett; Gillian E Caughey
Journal:  Drugs Aging       Date:  2018-01       Impact factor: 3.923

6.  Impact of 2015 Update to the Beers Criteria on Estimates of Prevalence and Costs Associated with Potentially Inappropriate Use of Antimuscarinics for Overactive Bladder.

Authors:  Brandon T Suehs; Cralen Davis; Daniel B Ng; Katherine Gooch
Journal:  Drugs Aging       Date:  2017-07       Impact factor: 3.923

Review 7.  Potentially inappropriate prescribing in community-dwelling older people across Europe: a systematic literature review.

Authors:  Eline Tommelein; Els Mehuys; Mirko Petrovic; Annemie Somers; Pieter Colin; Koen Boussery
Journal:  Eur J Clin Pharmacol       Date:  2015-09-26       Impact factor: 2.953

Review 8.  Benzodiazepine Misuse in the Elderly: Risk Factors, Consequences, and Management.

Authors:  Guillaume Airagnes; Antoine Pelissolo; Mélanie Lavallée; Martine Flament; Frédéric Limosin
Journal:  Curr Psychiatry Rep       Date:  2016-10       Impact factor: 5.285

Review 9.  Multimorbidity and polypharmacy in the elderly: lessons from REPOSI.

Authors:  Pier Mannuccio Mannucci; Alessandro Nobili
Journal:  Intern Emerg Med       Date:  2014-08-28       Impact factor: 3.397

10.  Changes in prescription patterns in older hospitalized patients: the impact of FORTA on disease-related over- and under-treatments.

Authors:  Farhad Pazan; Heinrich Burkhardt; Helmut Frohnhofen; Christel Weiss; Christina Throm; Alexandra Kuhn-Thiel; Martin Wehling
Journal:  Eur J Clin Pharmacol       Date:  2017-12-02       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.